Expert Opinion on Emerging Drugs
Last updated ISSN 1472-8214
Expert Opinion on Emerging Drugs is published by Taylor & Francis in medicine. It is a subscription journal. Its article processing charge is not published.
Is your paper a fit?
The surest way to know is to compare your own abstract against what this journal has actually been publishing, rather than against its aims-and-scope page. Paste your abstract and Journal Hunt will tell you how close Expert Opinion on Emerging Drugs is — and show you journals like it.
What it publishes
Recent work in Expert Opinion on Emerging Drugs concentrates on these topics, taken from its published record rather than from its own description:
- Asthma and respiratory diseases
- Retinal Diseases and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Psoriasis: Treatment and Pathogenesis
- HER2/EGFR in Cancer Research
- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Phosphodiesterase function and regulation
Key facts
| Publisher | Taylor & Francis |
|---|---|
| ISSN | 1472-8214, 1744-7623 |
| Subject area | Medicine |
| Access | Subscription |
| Article processing charge | Not published |
| Indexed in | Web of Science — Science Citation Index Expanded · Scopus |
| Articles published | 1,031 |
| Publishing since | 1997 |
| Journal website | informahealthcare.com/journal/emd |
Facts come from OpenAlex, DOAJ and Wikidata and may lag the journal’s own pages. Check the publisher’s site before submitting. Indexing shown here is what is recorded, not a complete picture — about a third of journals have no indexing recorded anywhere we can read, so “not recorded” does not mean a journal is absent from Scopus or Web of Science.
Journals like Expert Opinion on Emerging Drugs
Other established journals in medicine, if this one is not the right home for your paper: